uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto (NCT05874921)

🧪 Interventions in This Study

• Jelmyto (mitomycin) for pyelocalyceal solution (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (22 Sites)

• Providence St. Johns Health Center — Santa Monica, California
• University of Florida — Gainesville, Florida
• Mount Sinai Medical Center of Florida, Inc. — Miami, Florida
• H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. — Tampa, Florida
• Northwestern University — Chicago, Illinois
• Indiana University — Indianapolis, Indiana
• The State University of Iowa — Iowa City, Iowa
• Chesapeake Urology — Baltimore, Maryland
• Johns Hopkins Medical Center — Baltimore, Maryland
• Mass General Hospital (MGH) — Boston, Massachusetts
• The Brigham and Womens Hospital — Boston, Massachusetts
• University of Michigan — Ann Arbor, Michigan
• University of Missouri — Columbia, Missouri
• Rutgers — New Brunswick, New Jersey
• The Feinstein Institutes for Medical Research — Lake Success, New York
• NYU Grossman School of Medicine — New York, New York
• SUNY Upstate — Syracuse, New York
• The University of North Carolina Chapel Hill — Chapel Hill, North Carolina
• Ohio State University — Columbus, Ohio
• Medical University of South Carolina — Charleston, South Carolina
• UT Southwestern Medical Center — Dallas, Texas
• The University of Texas M.D. Anderson Cancer Center — Houston, Texas

📞 Contact the Study Coordinator

Phone: (855) 987-6436

Email: registry@urogen.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Urothelial Carcinoma

• Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) — Springdale, Arkansas
• Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma — Philadelphia, Pennsylvania
• A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma — Houston, Texas
• A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder — Bloomington, Indiana
• Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma — Oklahoma City, Oklahoma
• Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC — Tampa, Florida

Explore by condition: All Urothelial Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.